E-Seq Medical Overview
- Year Founded
-
2016
- Status
-
Private
- Latest Deal Type
-
Series A
- Investors
-
1
E-Seq Medical General Information
Description
Developer of gene sequencing products designed to provide genetic risk assessment of essential hypertension and cerebrovascular diseases. The company focuses on the research and development of susceptible gene testing products and uses artificial intelligence technology to provide gene sequencing services, enabling patients to improve their hypertension treatment efficiency.
Contact Information
Website
www.e-seq.comCorporate Office
- 3rd Floor, Building C,Innovation Building
- Zhongguancun Life Science Park
- Beijing
- China
Corporate Office
- 3rd Floor, Building C,Innovation Building
- Zhongguancun Life Science Park
- Beijing
- China
E-Seq Medical Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Early Stage VC (Series A) | 29-Nov-2018 | Completed | Generating Revenue |
E-Seq Medical Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Beijing LF Capital | Venture Capital | Minority |
E-Seq Medical FAQs
-
When was E-Seq Medical founded?
E-Seq Medical was founded in 2016.
-
Where is E-Seq Medical headquartered?
E-Seq Medical is headquartered in Beijing, China.
-
What industry is E-Seq Medical in?
E-Seq Medical’s primary industry is Other Healthcare Technology Systems.
-
Is E-Seq Medical a private or public company?
E-Seq Medical is a Private company.
-
What is E-Seq Medical’s current revenue?
The current revenue for E-Seq Medical is
. -
Who are E-Seq Medical’s investors?
Beijing LF Capital has invested in E-Seq Medical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »